Stoke Therapeutics (STOK) Times Interest Earned (2020 - 2026)
Stoke Therapeutics (STOK) posted quarterly Times Interest Earned of -$2322.5 for Q1 2026, down 102.09% year-over-year from $111240.0 in Q1 2025, and down 4035.55% quarter-over-quarter from -$56.16 in Q4 2025.
Stoke Therapeutics (STOK) Times Interest Earned (2020 - 2026) Analysis & Trends
Stoke Therapeutics' Times Interest Earned history runs 7 years deep, the most recent figure standing at -$2322.5 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 102.09% year-over-year to -$2322.5; the TTM figure through Mar 2026 stood at -$165.25 (down 436.62% YoY), while the FY2025 annual figure was -$0.11, up 97.75% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$2322.5, down from -$56.16 in the prior quarter.
- The five-year high for Times Interest Earned was $111240.0 in Q1 2025, with the low at -$14363.7 in Q3 2025.
- The 5-year median for Times Interest Earned is -$26.96 (2022), against an average of $5440.8.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned tumbled 71336.33% in 2024, then soared 8725.69% in 2025.
- Stoke Therapeutics' Times Interest Earned stood at -$0.28 in 2022, then rose by 20.05% to -$0.22 in 2023, then slumped by 7858.15% to -$17.66 in 2024, then plunged by 217.96% to -$56.16 in 2025, then tumbled by 4035.55% to -$2322.5 in 2026.
- Business Quant data shows STOK's Times Interest Earned at -$2322.5 in Q1 2026, -$56.16 in Q4 2025, and -$14363.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -22.89 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.89 |
| Mar 31, 2026 | -2,322.52 |
| Dec 31, 2025 | -56.16 |
| Sep 30, 2025 | -14,363.67 |
| Jun 30, 2025 | -4.69 |
| Mar 31, 2025 | 111,240.00 |
| Dec 31, 2024 | -17.66 |
| Jun 30, 2024 | -5,868.40 |
| Mar 31, 2024 | -1,289.64 |
| Dec 31, 2023 | -0.22 |
| Sep 30, 2023 | -158.34 |
| Jun 30, 2023 | -8.21 |
| Mar 31, 2023 | -41.29 |
| Dec 31, 2022 | -0.28 |
| Sep 30, 2022 | -15.94 |
| Jun 30, 2022 | -3.97 |
| Mar 31, 2022 | -36.25 |
| Dec 31, 2021 | -0.37 |
| Sep 30, 2021 | -8.70 |
| Jun 30, 2021 | -43.03 |